- Home
- HYFM vs NLSP Comparison
HYFM vs NLSP Comparison
Compare HYFM & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HYFM
- NLSP
- Stock Information
- Founded
- HYFM 1977
- NLSP 2015
- Country
- HYFM United States
- NLSP Switzerland
- Employees
- HYFM N/A
- NLSP N/A
- Industry
- HYFM Industrial Machinery/Components
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- HYFM Industrials
- NLSP Health Care
- Exchange
- HYFM Nasdaq
- NLSP Nasdaq
- Market Cap
- HYFM 15.0M
- NLSP 12.4M
- IPO Year
- HYFM 2020
- NLSP 2021
- Fundamental
- Price
- HYFM $3.11
- NLSP $1.84
- Analyst Decision
- HYFM
- NLSP
- Analyst Count
- HYFM 0
- NLSP 0
- Target Price
- HYFM N/A
- NLSP N/A
- AVG Volume (30 Days)
- HYFM 24.6K
- NLSP 940.1K
- Earning Date
- HYFM 11-06-2025
- NLSP 10-06-2025
- Dividend Yield
- HYFM N/A
- NLSP N/A
- EPS Growth
- HYFM N/A
- NLSP N/A
- EPS
- HYFM N/A
- NLSP N/A
- Revenue
- HYFM $161,102,000.00
- NLSP N/A
- Revenue This Year
- HYFM N/A
- NLSP N/A
- Revenue Next Year
- HYFM $37.86
- NLSP N/A
- P/E Ratio
- HYFM N/A
- NLSP N/A
- Revenue Growth
- HYFM N/A
- NLSP N/A
- 52 Week Low
- HYFM $1.50
- NLSP $1.30
- 52 Week High
- HYFM $8.55
- NLSP $5.64
- Technical
- Relative Strength Index (RSI)
- HYFM 39.39
- NLSP 42.28
- Support Level
- HYFM $2.96
- NLSP $1.81
- Resistance Level
- HYFM $3.17
- NLSP $2.15
- Average True Range (ATR)
- HYFM 0.25
- NLSP 0.19
- MACD
- HYFM 0.03
- NLSP -0.02
- Stochastic Oscillator
- HYFM 25.56
- NLSP 13.57
About HYFM Hydrofarm Holdings Group Inc.
Hydrofarm Holdings Group Inc is a distributor and manufacturer of agriculture equipment and supplies. Some of its products includes lighting solutions, growing media (i.e., premium soils and soil alternatives), nutrients, equipment, and supplies sold under proprietary, exclusive/preferred brands, or non-exclusive/distributed brands. The business is organized into two operating segments, the U.S. and Canada.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.